Advancing scientific knowledges for untreated serious diseases

4P-Pharma pipeline covers an extensive spectrum of therapeutic areas, encompassing chronic and autoimmune diseases, respiratory and infectious diseases, preventive therapies, and ophthalmological conditions.

Our pipeline reflects our commitment to shift the paradigm of classical drug development approaches and overcome traditional attrition rate for the benefit of patients. ​

Our approach is comprehensive and multifaceted, designed to meet the diverse challenges within the healthcare landscape.

  • Therapeutic areas
  • Candidate
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
Chronic and Autoimmune Diseases



Phase II

4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech. Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.

We are now entering Phase II of our study

≥ 595 Millions of people have OA in the world (Kloppenburg et al., 2020). Estimated sales per year: 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)



Drug discovery

With our partner, Oncocross, a Korea based AI tech company, we are developing an AI platform-based treatment for systemic sclerosis.

Systemic sclerosis (SSc) is a rare autoimmune disease with an estimated prevalence of 242 to 660 cases per million adults, varying geographically, and is more common in women with a 5:1 female-to-male ratio. It’s characterized by extensive tissue fibrosis and vascular abnormalities, affecting not only the skin but also internal organs, distinguishing it from localized scleroderma. The disease primarily manifests in two forms: Limited cutaneous SSc and Diffuse cutaneous SSc, each with different levels of severity and organ involvement (for review Adigun et al., 2022)


Primary Sclerosing Cholangitis (PSC)

Drug discovery

In partnership with Delta4, an AI tech company based in Vienna (Austria), we join forces to discover and develop a drug candidate from Delta4’s platform, for the treatment of PSC.

Primary sclerosing cholangitis (PSC) is a rare liver condition, characterized by inflammation and scarring of the bile ducts leading to liver failure, and it predominantly affects individuals between 30 and 40 years old, more commonly in men. It has a low incidence and prevalence rate, ranging from 0 to 1.3 cases per 100,000 people per year, with a median survival of about 10 years without liver transplantation. The disease is more prevalent in North America and Northern Europe compared to Asia, and there is a notably higher risk among siblings of affected individuals, particularly in nonsmokers ( for review: Rawla and Samant, 2023)

Respiratory and infectious disease


Respiratory Infection

Phase II

4P021 is a CXCR4 antagonist for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications. 4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille. Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.

IA wide variety of aetiologies can lead to ARDS. Pneumonia, extrapulmonary sepsis, aspiration of gastric contents, noncardiogenic shock, transfusion, and severe trauma. Despite some improvements in ARDS supportive care, this syndrome still induces a high mortality rate. Indeed, the overall mortality rate is 43%.

Preventive Therapies


Stimulant addiction



Ophtalmological diseases


Stargardt disease (orphan)


4P020 is a beta-3 adrenergic receptor agonist developed as a new first-in-class therapeutic drug for Stargardt disease in collaboration with Institut de la Vision and SATT Lutech.

Stargardt disease is a rare disease with an estimated prevalence of 1/8,000 – 1/10,000 individuals.(Orphanet)


Dry Age-related Macular Degeneration


4P020 is a beta-3 adrenergic receptor agonist developed as a new first-in-class therapeutic drug for dry AMD in collaboration with Institut de la Vision and SATT Lutech.

With population ageing worldwide, it is estimated that the number of people affected by dry AMD will increase to 230 – 259 Millions in 2040 (Deng et al., 2021)

Get in touch Quit ×